Download Free Quality Of Life And Pharmacoeconomics In Clinical Trials Book in PDF and EPUB Free Download. You can read online Quality Of Life And Pharmacoeconomics In Clinical Trials and write the review.

The Second Edition of this groundbreaking work refines the art and science of quality of life assessment and pharmacoeconomics and redefines the role of these evaluation parameters in clinical trials and health care decision-making. Dr. Spilker has assembled more than 200 experts from diverse clinical, research, and social science disciplines to provide a comprehensive reference on the methodology, interpretation, and use of quality of life and pharmacoeconomic studies. Expanded to four times its predecessor's size and scope, the Second Edition features: all-new sections on pharmacoeconomics and crucial health policy issues such as outcomes research a new, extensive section on cross-cultural and cross-national issues in quality of life assessment detailed information on specific tests and measures of quality of life comprehensive guidelines on choosing and administering tests and analyzing, interpreting, and presenting data many chapters on new topics such as phenomenology, assessment of spiritual status, and alternative/complementary medical treatments.
Based on Dr. Spilker's classic Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd Edition, this streamlined sourcebook offers an easy-to-understand introduction to an increasingly critical aspect of health care. Seven succinct sections review key aspects of health-related quality of life and the essentials of pharmacoeconomics, providing expert answers to your most pressing questions: What generic HRQOL and disease-specific assessments are available? How are these scales chosen, used, and interpreted? What instruments do I need...and where can I find them? What is the relationship between pharmacoeconomics and quality of life? Between outcomes research and quality of life? Well-organized and easy to use, Quality of Life and Pharmacoeconomics: An Introduction will become a standard textbook for professionals and students in all areas of medical research and practice.
Researchers in all clinical fields are fully aware of the importance of Quality of Life measurements in judging the efficacy of a given treatment. Psychological criteria play an important role in this evaluation. Assessment of Quality of Life in Clinical Trials: methods and practice explores the current state of the art and illustrates the benefits and potential of health related quality of life assessment in clinical trials. It covers a wide range of analytical issues, emphasizing new and innovative approaches that are of practical and clinical importance.
Understanding Health Outcomes and Pharmacoeconomics presents an overview of the tools used to assess patient-related health status including associated health outcomes and the analyses that are used to determine cost-effectiveness in evaluating pharmacotherapeutic interventions to improve health. Including data and examples from several different countries, this comprehensive text will help students understand the basis for decisions made at the local and governmental level that impact the use of pharmaceuticals and provide a strong foundation for understanding the principles used in cost-effective decision making. With commentaries, cases studies, and highlighting international differences, this text concludes with a discussion of the need for a universal system for documenting medication use. Understanding Health Outcomes and Pharmacoeconomics provides definitions of comparative effectiveness research (CER) and comparisons of pharmacoeconomic models (including cost-effectivess, cost-benefit, and cost utility analyses). This inclusive text provides describes how CER is linked to various pharmacoeconomic models by providing examples from clinical trials with comparative pharmacotherapy and cost parameters. From the Introduction: "The need for interprofessional education was made apparent in the 2003 Health Professions Education: A Bridge to Quality report. All healthcare professionals must be educated to deliver patient-centered care as members of an interprofessional team, emphasizing evidence-based practice, quality improvement approaches, and informatics. An enhanced understanding of pharmacoeconomic principles is a step in the right direction for healthcare practitioners as we do our best to ensure optimal medication therapy outcomes for patients and society at-large." -- George E. MacKinnon III, PhD, RPh, FASHP
Get a healthy perspective on pharmaceutical economics! Strategies in Pharmacoeconomics and Outcomes Research presents a comprehensive introduction to the economic aspects of the health sector, focusing on strategies for the development and marketing of healthcare products. A much-needed addition to this relatively new field, the book narrows health economics into the sub-discipline of pharmacoeconomics, bridging the gap between different interest groups in the pharmaceutical industry-research and development at one end, sales and marketing at the other. Using basic terminology and practical examples with descriptive tables and figures, it analyzes the implications of projecting costs of pharmaceutical products as a method of determining the viability of their development. Written from an international perspective, Strategies in Pharmacoeconomics and Outcomes Research examines the costs of drug therapy on health care systems and society through global marketing and modeling strategies, including clinical research and trial examples. Through the interlinked concepts of clinical research, outcomes research and pharmacoeconomics, the book evaluates the effectiveness of health technologies under “real world” circumstances or “normal” medical practice to achieve the optimum benefit from the resources available. The research process follows the economics of a drug?s efficacy (how it works under ideal circumstances) to its effectiveness (how it does in “real” life) to its efficiency (how cost-effective it is) in determining the baseline effects of a disease on economic and humanistic parameters. Strategies in Pharmacoeconomics and Outcomes Research also examines: resources and cost benefits (direct, indirect, intangible, and quality of life) health economical models (decision-tree analysis, Markov-model) reimbursement differences between countries due to the rate of currency exchange drug monitoring and regulation . . . and includes an extensive glossary! At a time when health economics has become increasingly important, Strategies in Pharmacoeconomics and Outcomes Research is an essential tool for the pharmaceutical, diagnostic, and medical device industries to ensure the most efficient use of limited resources. The book?s practical tone and common-sense methods provide a realistic approach that will benefit pharmaceutical and medical professionals, product managers, business development managers, drug regulatory affairs officials, and clinical study coordinators in making strategic and operational decisions about pharmaceutical development, production, or consumption.
Fully updated and substantially expanded, this second edition of the well-known ACCP publication will enable practicing pharmacists and pharmacy students to develop knowledge and skill to measure and evaluate economic and patient-based outcomes. Learn How to Measure and Evaluate Economic and Patient-based Outcomes
This book provides a reference guide describing the current status of medication in all major psychiatric and neurological indications, together with comparisons of pharmacological treatment strategies in clinical settings in Europe, USA, Japan and China. In addition, it highlights herbal medicine as used in China and Japan, as well as complementary medicine and nutritional aspects. This novel approach offers international readers a global approach in a single dedicated publication and is also a valuable resource for anyone interested in comparing treatments for psychiatric disorders in three different cultural areas. There are three volumes devoted to Basic Principles and General Aspects, offering a general overview of psychopharmacotherapy (Vol. 1); Classes, Drugs and Special Aspects covering the role of psychotropic drugs in the field of psychiatry and neurology (Vol. 2) and Applied Psychopharmacotherapy focusing on applied psychopharmacotherapy (Vol. 3). These books are invaluable to psychiatrists, neurologists, neuroscientists, medical practitioners and clinical psychologists.
It is becoming increasingly important to examine the relationship between the outcomes of a clinical trial and the costs of the medical therapy under study. The results of such analysis can affect reimbursement decisions for new medical technologies, drugs, devices or diagnostics. It can aid companies seeking to make claims about the cost-effectiveness of their product, as well as allowing early consideration of the economic value of therapies which may be important to improving initial adoption decisions. It is also vital for addressing the requirements of regulatory bodies. Economic Evaluation in Clinical Trials provides practical advice on how to conduct cost-effectiveness analyses in controlled trials of medical therapies. This new edition has been extensively rewritten and revised; topics discussed range from design issues such as the types of services that should be measured and price weights, to assessment of quality-adjusted life years. Illustrative materials, case histories and worked examples are included to encourage the reader to apply the methods discussed. These exercises are supported with datasets, programmes and solutions made available online.
Designed as a true introduction to the subject, Essentials of Pharmacoeconomics: Health Economics and Outcomes Research, ThirdEdition includes information on fundamental topics, defines terminology, and provides examples for evaluating published research, making it perfect for any pharmacy student or practitioner new to the topic. This updated edition provides the critical foundations of knowledge for measuring costs and health-related quality-of-life (HRQoL) and evaluating the four types of studies (CMA, CEA, CUA, and CBA); it also explains Markov and Budget Impact Analysis modeling, and discusses the advantages and disadvantages of using retrospective databases and real-world data (RWD). Additionally, the text summarizes the use of pharmacoeconomic evaluations by decision makers outside of the United States and the extent to which pharmacoeconomic data are used to make decisions in the United States, includes barriers to its use, and discusses future issues. All of this information is designed to ensure preparedness to improve clinical and humanistic outcomes based on available resources.